## **David Charles Hutchings**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4982445/publications.pdf

Version: 2024-02-01

1477746 1473754 9 285 9 6 citations h-index g-index papers 9 9 9 506 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	The Control of Diastolic Calcium in the Heart. Circulation Research, 2020, 126, 395-412.	2.0	94
2	Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality. Heart, 2016, 102, 1750-1756.	1.2	74
3	Phosphodiesterase-5 inhibitors and the heart: compound cardioprotection?. Heart, 2018, 104, 1244-1250.	1.2	63
4	Phosphodiesterase 5 inhibition improves contractile function and restores transverse tubule loss and catecholamine responsiveness in heart failure. Scientific Reports, 2019, 9, 6801.	1.6	34
5	PDE5 Inhibition Suppresses Ventricular Arrhythmias by Reducing SR Ca <sup>2+</sup> Content. Circulation Research, 2021, 129, 650-665.	2.0	8
6	Interaction of background Ca <sup>2+</sup> influx, sarcoplasmic reticulum threshold and heart failure in determining propensity for Ca <sup>2+</sup> waves in sheep heart. Journal of Physiology, 2022, 600, 2637-2650.	1.3	7
7	Ventricular arrhythmias complicating hypertrophic cardiomyopathy. British Journal of Hospital Medicine (London, England: 2005), 2012, 73, 502-508.	0.2	2
8	The Diagnostic and Prognostic Utility of Contemporary Cardiac Magnetic Resonance in Suspected Acute Myocarditis. Diagnostics, 2022, 12, 156.	1.3	2
9	Letter by Hutchings et al Regarding Article, "Preimplant Phosphodiesterase-5 Inhibitor Use Is Associated With Higher Rates of Severe Early Right Heart Failure After Left Ventricular Assist Device Implantation : An INTERMACS Analysis― Circulation: Heart Failure, 2019, 12, e006410.	1.6	1